Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: 2MAR$ who wrote (17775)	7/14/1999 2:59:00 PM
From: Blitz	Read Replies (2) \| Respond to of 25711

Thanks! eom. Also: for anyone watching PRXX... Patents approved! News just out Wednesday July 14, 2:38 pm Eastern Time Company Press Release SOURCE: Praxis Pharmaceuticals, Inc. Patent Approval by Rothschild Tele-Conference Planned for July 15, 4:15 p.m.(EDT) CANBERRA, Australia and VANCOUVER, British Columbia, July 14 /PRNewswire/ -- Praxis Pharmaceuticals, Inc. (OTC Bulletin Board: PRXX - news), in its news release dated July 9, 1999 had presented a summary of the terms of the proposed equity investment by Rothschild Bioscience Unit, a division of the worldwide Rothschild group, which was subject to a patent approval. Praxis Pharmaceuticals, Inc. is very pleased to announce that the patent issues have been approved and the proposed deal will now go to shareholders for approval. The date of the meeting to approve the deal has been changed to August 16, 1999 to facilitate a full voter response. Due to a tremendous investor response the company will be holding a tele-conference call at 4:15 p.m. EDT with Dr. William Cowden, CEO and Dr. Brett Charlton, President, to discuss the proposed deal and other corporate developments. The conference call will be open to analysts, stockbrokers and investors. In North America those wishing to participate in the call should phone, toll free, at 888-867-5802 and outside of North America 847-619-6054. Please mention the host, David Stadnyk. On Behalf of the Board of Directors, David Stadnyk Director, Secretary Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995. This news release contains forward-looking statements. All such forward-looking statements are, by necessity, only estimates of future results and actual results achieved by Praxis may differ materially from these statements due to a number of factors. Praxis assumes no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such statements. You should independently investigate and fully understand all risks before making investment decisions. SOURCE: Praxis Pharmaceuticals, Inc. -------------------------------------------------------------------------------- More Quotes and News: Praxis Pharmaceuticals Inc (OTC BB:PRXX - news) Related News Categories: health care, medical/pharmaceutical